Indeed, pretreatment for 30 min with the anti-Parkinson drug Rasagiline (0.1 nM), an MAO-B inhibitor with neuroprotective properties in PD (Mandel et al. 2005a, b; Weinreb et al. 2010), significantly increased the cell survival index (twofold over non-treated cells) of ALDH1A1-deficient cells at 10 μM of DA, but rasagiline could not overcome the massive cell death (98%) induced by 15 μM of DA (Fig. 19, right panel). This evidence concerns the gene MAOB and Parkinson disease.